No way! But... [Design Issues]

posted by wienui  – Germany, Oman, 2019-12-07 04:01 (414 d 22:57 ago) – Posting: # 20955
Views: 3,682

(edited by wienui on 2019-12-07 06:47)

Dear all,

» So here two answers - theoretically there is no problem to use all data, but regulatory authorities can bann you for it. (IMHO)

I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?

Best regards,
Osama

Cheers,
Osama

Complete thread:

Activity
 Admin contact
21,310 posts in 4,445 threads, 1,489 registered users;
online 3 (0 registered, 3 guests [including 3 identified bots]).
Forum time: Monday 02:58 CET (Europe/Vienna)

Science may set limits to knowledge,
but should not set limits to imagination.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5